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Abstract Angiotensin I-converting enzymes (ACEs) are zinc
metallopeptidases that cleave carboxy-terminal dipeptides from
short peptide hormones. We have determined the crystal struc-
tures of AnCE, a Drosophila homolog of ACE, with and without
bound inhibitors to 2.4 A$ resolution. AnCE contains a large
internal channel encompassing the entire protein molecule.
This substrate-binding channel is composed of two chambers,
reminiscent of a peanut shell. The inhibitor and zinc-binding
sites are located in the narrow bottleneck connecting the two
chambers. The substrate and inhibitor speci¢city of AnCE ap-
pears to be determined by extensive hydrogen-bonding networks
and ionic interactions in the active site channel. The catalyti-
cally important zinc ion is coordinated by the conserved Glu395
and histidine residues from a HExxH motif.
- 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Angiotensin I-converting enzyme (ACE) is a zinc metallo-
peptidase that cleaves a C-terminal dipeptide. ACE plays an
important role in regulating blood pressure maintenance and
heart function by catalyzing the production of the hyperten-
sive peptide, angiotensin II, as well as the destruction of the
hypotensive peptide, bradykinin [1,2]. Speci¢c inhibitors of
ACE such as captopril and lisinopril are highly e¡ective as
antihypertensive drugs and are widely used in the clinic [3,4].
Two types of human ACE are known. The somatic form of
ACE contains two homologous domains of about 600 amino
acids; both domains contain an intact zinc-binding site critical
for catalysis [5]. However, the testicular form of human ACE
contains only one domain that is essentially identical to the
C-terminal domain of somatic ACE [6,7]. ACEs are an evo-
lutionarily conserved family of proteins. Two Drosophila ho-
mologs of ACE, AnCE and Acer, have been reported [8^11].
The Drosophila ACEs contain a single ACE domain, similar
to the testicular form of human ACE. The sequence identity
between human testicular ACE and Drosophila AnCE is 42%
overall and reaches higher than 70% in the regions surround-
ing the enzyme active site [8,9]. AnCE can hydrolyze angio-
tensin I and many of the other known substrates of human
ACE [12,13]. The activity of AnCE is inhibited by various
inhibitors of human ACE with high potency [12,14]. These
data suggest that the catalytic mechanism and structure of
the enzyme are conserved in the Drosophila AnCE. The cata-
lytic mechanism of ACE has been proposed based on that of
thermolysin, a zinc metallopeptidase, because they share a
HExxH zinc-binding motif [15,16]. However, other than this
short peptide motif, the sequence homology of ACE with
other zinc proteases is minimal, and the exact molecular
mechanism of ACE action has not been clearly identi¢ed.
We have determined the crystal structure of AnCE, with
and without the inhibitors captopril and lisinopril.
2. Materials and methods
Complementary DNA of Drosophila AnCE (residues 1^615) was
obtained from a Drosophila QuickClone cDNA library (Clontech)
using the polymerase chain reaction, and was con¢rmed by DNA
sequencing. AnCE cDNA, tagged with six histidine codons at the
C-terminus, was cloned into the pVL1393 baculovirus transfer vector
(Pharmingen). The hexahistidine-tagged AnCE fusion protein was se-
creted into the culture medium of Hi5 cells (Clontech) after virus
infection. The culture medium was harvested after 2 days of viral
infection. The secreted AnCE was puri¢ed using TALON metal a⁄n-
ity chromatography (Clontech), Source-Q anion exchange and Super-
dex-200 gel ¢ltration chromatography (Amersham Pharmacia Bio-
tech). The puri¢ed protein was concentrated to 20^25 mg/ml in a
bu¡er containing 20 mM HEPES, 0.2 M NaCl (pH 7.5). Crystals
were grown at 22‡C, using the hanging-drop vapor di¡usion method,
by mixing 2 Wl of the protein solution and 2 Wl of crystallization bu¡er
containing 7.2 M sodium formate, 2 mM ZnCl2. The crystals contain-
ing bound inhibitors were grown with an additional 2 mM of capto-
pril or lisinopril added to the protein solution. Crystals suitable for
di¡raction experiments were obtained after 1 week.
Data from AnCE crystals containing lisinopril or captopril were
collected at the Cornell High Energy Synchrotron Source in Ithaca,
NY, USA, on the A1 beamline using the ADSC Quantum 4 detector
at V=0.9280 AM . The native and heavy atom derivative data were
collected using a rotating-anode X-ray generator and an R-AXIS IV
detector. Intensities were integrated, reduced, scaled and post-re¢ned
with the HKL package (HKL Research). The crystals belong to P21
space group with unit dimensions a=94.5 AM , b=121.3 AM , c=94.5 AM
and L=99.1‡. The crystallographic asymmetric unit contains two pro-
tein molecules. Data collection statistics are summarized in Table 1.
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The native structure without a bound inhibitor was determined by
MIR procedures using the SOLVE 2.03 program [17]. The initial
phases were signi¢cantly improved by two-fold non-crystallographic
symmetry (NCS) averaging, solvent £attening and histogram match-
ing, using the RESOLVE 2.03 program [17]. Most K-helices could be
automatically traced by the RESOLVE 2.03 and Refmac 5.0 [18]. The
resulting electron density map showed clear densities for most of the
backbone and side chains and the majority of the side chain atoms
were built in the ¢rst round of manual modeling using program O
[19]. Errors in the initial modeling were corrected in the subsequent
simulated annealed re¢nement and manual remodeling using the CNS
[20] and O programs. The NCS-related atoms were tightly restrained
throughout the re¢nement process, except during the last cycle. The
re¢ned structure without a bound inhibitor was used as an initial
model for re¢nement with data from crystals containing captopril
or lisinopril. The partially re¢ned Fo3Fc di¡erence Fourier electron
density map showed clear densities for the inhibitor molecules lisino-
pril and captopril. The atomic coordinates for lisinopril and captopril
were obtained from the Cambridge Structural Database. The £exible
torsion angles of lisinopril were manually adjusted initially and then
re¢ned using the CNS program. The overall protein geometry of the
¢nal re¢ned structure was good, with an absence of non-Gly, non-Pro
residues in the disallowed regions of the Ramachandran plot.
3. Results and discussion
3.1. Structure of AnCE
The crystal structures of AnCE were determined using the
multiple isomorphous replacement technique with data to
2.4 AM resolution. AnCE is 615 amino acids long and its struc-
ture is composed of 21 K-helices and three antiparallel
L-strands (Fig. 1). AnCE contains a large internal channel
encompassing the entire protein molecule; this highly unusual
substrate-binding channel is composed of two chambers, rem-
iniscent of a peanut shell. The zinc ion critical for catalysis is
located in the narrow bottleneck connecting these two cham-
bers.
The zinc ion is penta-coordinated by the conserved residues
Glu395, His367 and His371, and two water molecules in the
absence of a bound inhibitor (Fig. 2A). Mutations of these
metal-coordinating residues of human somatic ACE result in
complete inactivation of the enzyme, emphasizing the crucial
role of zinc in catalysis [21,22]. Asp399 indirectly coordinates
zinc through interaction with His367, via hydrogen bonding.
Mutation of Asp399 to an alanine has a more subtle e¡ect,
reducing kcat by 22-fold [22]. The zinc coordination geometry
of ACE is identical with that of the gluzincin family of zinc
metalloproteases, which contain the HExxH motif [16].
Captopril is a competitive inhibitor of ACE, and binds to
human ACE and Drosophila AnCE with Kis of 1.4 and 1.1
nM, respectively [14]. Captopril mimics two carboxy-terminal
residues of the enzyme substrate. The sulfhydryl group of
captopril replaces the zinc-binding water molecule and di-
rectly interacts with the zinc ion, with a distorted tetrahedral
geometry (Fig. 2B). The carboxy-end of the proline moiety is
held by three highly conserved residues, Gln265, Lys495 and
Tyr504, through ionic and hydrogen bonds. These residues
probably prevent sliding of the substrate from the catalytic
site in the large enzyme internal channel. This kind of locking
mechanism may slip when the negative charge of the carboxy-
terminus is masked by amidation. For most substrates, ACE
cleaves the carboxy-terminal dipeptide, but it can hydrolyze
three amino acids from substance P and luteinizing hormone-
releasing hormone whose carboxy-termini are modi¢ed by
amidation [1]. The sulfhydryl group and the terminal proline
moieties of captopril are connected by a peptide bond. The
position of the carbonyl oxygen of the peptide bond is locked
by three strong hydrogen bonds with residues His337, His497
and Tyr507. Mutation of the His1089 residue of human so-
matic ACE, corresponding to the His497 residue of Drosophi-
la AnCE, abolishes binding of captopril and lisinopril to the
enzyme [23].
Lisinopril is another highly e⁄cient inhibitor of ACE. It
binds to the C-domain of human somatic ACE with a Ki of
0.2 nM and to Drosophila AnCE with a Ki of 18 nM [12,14].
Similar to captopril, lisinopril appears to mimic peptide sub-
strates. The residue that mediates binding of the carboxy-ter-
minal proline moiety of captopril is also involved in binding
of the proline moiety of lisinopril (Fig. 2C). In comparison to
captopril, lisinopril contains an additional lysine and a phenyl
group. The lysine side chain of lisinopril makes water-medi-
ated hydrogen bonds with residues Thr364 and Asp360. Ionic
interactions with the negatively charged Asp360, Asp146 and
Glu150 also enhance binding of the lysine group. Asp146 and
Asp360 are conserved or replaced by glutamates in human
ACEs. Similar to captopril, the His337 and His497 residues
interact with the carbonyl oxygen of the peptide bond con-
necting the terminal proline and lysine moiety of lisinopril.
The secondary amine group connecting the lysine and the
amino-terminal phenyl group of lisinopril makes a strong hy-
drogen bond with the backbone carbonyl oxygen of Ala338.
In lisinopril and related inhibitors, the carboxylic group, in-
stead of the sulfhydryl group, mediates zinc chelation. These
two carboxylic oxygens make direct coordination to zinc with
penta-coordinated geometry, and appear to mimic the nucle-
ophilic water and the carbonyl oxygen of the substrate in the
tetrahedral intermediates during the enzymatic reaction. Sim-
ilar penta-coordinated zinc chelation geometry is found in
thermolysin bound to transition-state mimicking inhibitors
(see below). The conserved Glu368 and Tyr507 side chains
make close contacts with the metal-coordinating carboxylic
oxygens of lisinopril. Residues directly involved in the zinc
and inhibitor binding are completely conserved in the known
ACE sequences (see web supplementary data2).
3.2. The substrate speci¢city of ACE
The substrate-binding site of AnCE is a large continuous
internal channel (Fig. 3). This peanut shell-shaped channel is
composed of two chambers of unequal size. The larger cham-
ber is the binding site of the amino-terminal eight amino acids
of the substrate angiotensin I, and will be referred to as the
‘N-chamber’ in this article. The carboxy dipeptide portion of
the substrate binds to the smaller chamber, and will be re-
ferred to as the ‘C-chamber’. The N- and C-chambers are 8.5
and 7.0 AM long, and 6.3 and 5.0 AM wide at their widest points,
respectively. These spacious chambers are su⁄ciently large for
the binding of short substrate peptides. However, size limita-
tions of the internal channel prevent binding and hydrolysis of
longer peptides or globular proteins. The catalytic zinc and
inhibitor binding sites are located in the narrow bottleneck
connecting the two chambers. The N- and C-chambers are
open to the exterior solvent area through narrow holes with
approximate diameters of 3 AM , which appear to be too small
for the passage of peptide substrates. Flexibility and a breath-
2 http://www.elsevier.com/locate/febs
FEBS 27024 28-2-03 Cyaan Magenta Geel Zwart
H.M. Kim et al./FEBS Letters 538 (2003) 65^7066
ing motion of the opening holes are probably required for
e⁄cient catalysis.
The main interactions between AnCE and substrate-mim-
icking inhibitors are mediated by ionic and hydrogen bonds.
The inhibitors cannot ¢ll up the spacious substrate-binding
channel and the shape of the inhibitors or substrates appears
to have a minor role in determining speci¢city of the enzyme.
ACE is a relatively non-speci¢c dipeptidase. However, it has
weak but noticeable tendencies in substrate selection. ACE
generally favors a hydrophobic residue at the carboxy-termi-
nus of the substrate [24]. The binding surface of the carboxy-
terminal proline moieties of the inhibitors is composed of a
hydrophobic patch provided by residues Phe441, Phe444,
Phe511, Tyr504 and Tyr507 of AnCE. This conserved patch
may be involved in the binding of bulky hydrophobic residues
such as isoleucines or phenylalanines in ACE substrates. The
substrate-binding channel of AnCE is predominantly nega-
tively charged (Fig. 3). This may explain why human and
Drosophila ACEs generally favor positively charged substrates
[1,25]. Negatively charged amino acids are sometimes found at
the amino-terminus but rarely in the middle of the sequences
of the known ACE substrates [1,13].
Fig. 1. Schematic diagram of the Drosophila AnCE structure. The zinc ion and the bound inhibitor, captopril, are shown in green and red, re-
spectively.
Table 1
Crystallographic statistics
Di¡raction data
Data set Native Captopril Lisinopril
Dmin (AM ) 2.6 2.4 2.4
Number of measurements 442 229 590 560 547 813
Unique re£ections 66 143 82 133 82 806
% Complete (outer shell) 92.8 (81.7) 90.8 (76.4) 92.2 (79.6)
I/c (outer shell) 23.9 (6.0) 19.5 (3.0) 22.1 (4.7)
Rmerge (%) (outer shell) 6.3 (23.4) 5.9 (37.5) 5.4 (23.3)
Phasing
Derivative Mercury chloride Methyl mercury chloride Trimethyl lead acetate Lead nitrate
Concentration (mM) 5 5 10 10
Temperature (‡C) 22 22 22 22
Soaking time (h) 10 2 24 48
Number of sites 7 10 6 3
Phasing powera 0.82 0.89 0.68 0.47
Mean ¢gure of meritb 0.56
Re¢nement
Data set Native Captopril Lisinopril
Data range (AM ) 20^2.6 20^2.4 20^2.4
R factor (%) 24.6 24.1 23.4
Rfree factor (%) 28.1 28.3 28.0
Rms deviations
Bond lengths (AM ) 0.008 0.009 0.009
Bond angles (‡) 1.5 1.5 1.4
NCS-related atoms (AM ) 0.028 0.029 0.022
Mean B factors (AM 2) 22.0 26.3 23.5
Number of protein atoms 9800 9800 9800
Number of solvent atoms 500 600 600
aPhasing power= GFf/E where GFf is the root mean square heavy atom structure factor and E is the residual lack of closure error.
bFigure of merit = cosine of the likely error in the phase angles.
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ACE2 is a recently discovered homolog of ACE [26,27].
ACE2 shares high sequence homology with ACE. Residues
Glu395, His367 and His371, coordinating zinc, or residues
Glu368, Tyr507 and His497, critical for the catalysis of
AnCE, are completely conserved in both ACE and ACE2
(see web supplementary data2). Surprisingly, ACE2 cleaves a
single amino acid rather than a dipeptide from the substrate.
The classical inhibitors of ACE, including captopril and lisi-
Fig. 2. Close-up view of the active site. A: The zinc ion without a bound inhibitor is penta-coordinated by conserved protein residues and two
water molecules. The zinc ion and coordinating water molecules are shown as green and red balls, respectively. The potential hydrogen-bonding
partners are connected by broken red lines. The broken green lines represent the metal coordination bonds. B: The active site with a bound
captopril is schematically drawn in the left panel. The chemical structure of captopril is shown in the top right panel. Fo3Fc di¡erence electron
density map calculated with the protein structure re¢ned without the inhibitor is contoured at 1.7c and superimposed with the ¢nal re¢ned
model including captopril (bottom right panel). C: The active site with a bound lisinopril is schematically drawn in the left panel. The chemical
structure of lisinopril (top right panel) and Fo3Fc di¡erence electron density map (bottom right panel), calculated as for B, are shown.
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nopril, do not bind to ACE2 [26,27]. To explain the remark-
able di¡erences in substrate and inhibitor speci¢city, we built
models of human ACE and ACE2 based on our crystal struc-
ture. Homology modeling of human testicular ACE and
ACE2 was performed using the program Swiss-Model [28]
or Modeller6 v.2 [29]. The molecular modeling was straight-
forward owing to the high sequence homology, and both tech-
niques gave essentially identical results. This study reveals two
signi¢cant changes that may a¡ect substrate binding and hy-
drolysis. In the AnCE structure, Gln265 makes a hydrogen
bond to the terminal carboxylic group of substrate-mimicking
inhibitors. This residue is changed to an arginine in ACE2 (see
web supplementary data2). The long and positively charged
side chain of the arginine may shift the substrate by one
amino acid, and the carboxy-terminus, instead of the second
terminal peptide bond, may be positioned to the catalytic site.
Arg500 of ACE2, which replaces Ser510 of AnCE, is also
located in close proximity to the carboxy-terminal residue
and may have a similar role. In addition to these changes,
residues Lys495 and Tyr504, which interact with terminal
carboxylic oxygens in AnCE, are changed in ACE2.
3.3. Comparison with other zinc metallopeptidases
ACE belongs to the gluzincin family of metalloproteases
[16]. Proteins of this family have minimal sequence homology
apart from their conserved HExxH zinc-binding motif. The
catalytic mechanism of a bacterial gluzincin, thermolysin, has
been extensively studied and has served as a prototype of the
HExxH-containing zinc proteases [15,16]. Other than this
short zinc-binding motif, thermolysin and ACE share no se-
quence or structural homologies. However, the zinc coordina-
tion geometry, and some residues critical for the hydrolysis,
are conserved between these two enzymes, suggesting that ca-
talysis by ACE may proceed through a reaction mechanism
Fig. 3. Cross-sectional view of the substrate-binding channel. The view is rotated approximately 90‡ counterclockwise about the vertical axis of
the right panel of Fig. 1. The metal ion and bound inhibitor are shown in green and red, respectively. The red and blue mesh represents nega-
tively and positively charged surface, respectively.
Fig. 4. Proposed reaction intermediates of AnCE (A) and thermolysin (B). His337 and His497 of AnCE are located close to Tyr507 and may
have an e¡ect on catalysis. The scissile peptide bonds are marked with curved red lines.
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similar to that of thermolysin. In thermolysin, Glu143 plays a
pivotal role by polarizing a nucleophilic water molecule and
by shuttling protons to the substrate (Fig. 4B). Glu368 in
AnCE occupies a nearly identical position and probably plays
a similar role in the ACE reaction mechanism (Fig. 4A).
His231 and Tyr157 residues in thermolysin are critical for
the enzyme activity; they promote formation of the tetrahe-
dral intermediate by stabilizing negative charges. In thermo-
lysin, the acidity of His231 is enhanced by the Asp226 residue
located close to His231. The position of His231 in thermolysin
is occupied by Tyr507 in AnCE, which suggests that Tyr507
may have a similar role in ACE catalysis. A residue that may
replace Asp226 of thermolysin is not found in the AnCE
structure. Instead, the AnCE active site includes His497,
which is separated by 3.3 AM from Tyr507. His497 is located
more than 5 AM away from the presumed binding site of the
catalytic carbonyl group of the substrate, and is unlikely to
play a direct role in stabilizing the tetrahedral intermediate.
Mutation of the His1089 residue of human somatic ACE,
corresponding to the His497 residue of Drosophila AnCE,
reduces the kcat by 100-fold, with only a mild increase of
Km [23]. These mutation data support the hypothesis that
His497 of AnCE plays a role similar to that of Asp226 in
thermolysin. It requires further study to clarify the role of
His497 in AnCE catalysis. Interestingly, AnCE contains an
additional histidine residue, His337, near the catalytic site.
His337 is highly conserved in human and Drosophila ACEs
and is located 4 AM from His497. The interaction network
formed by His337, His497 and Tyr507 in AnCE may play a
role in stabilizing the transition state during catalysis.
The overall shape of AnCE resembles several other zinc
metalloproteases, such as neurolysin and neprilysin, which
cleave short peptide hormones [30,31]. These enzymes have
their active sites in the large internal chambers that restrict
entry of the larger substrates. The topology of AnCE is practi-
cally identical to that of neurolysin but is di¡erent from that
of neprilysin. Therefore, AnCE and neprilysin may represent a
case of convergent evolution.
4. Note added in proof
While this paper was in press, an independent crystal struc-
ture of human testicular ACE was reported [32].
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